Darodipine
| |
| Names | |
|---|---|
| Preferred IUPAC name
Diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate | |
| Other names
4-(2,1,3-Benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C19H21N3O5 | |
| Molar mass | 371.393 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Darodipine is an experimental calcium channel blocker that based on animal models may reduce neuronal cytoskeletal alterations during aging and in neurodegenerative disorders. Studies performed on rats have shown darodipine to have an effect on brain serotonergic systems. Darodipine increased the 5-HIAA/5-HT ratio within various parts of the brain.[1] Darodipine has also been shown to impair memory and learning processes on mice.[2]
The longterm effect of darodipine was tested in the rats and it shows that there is no significant change in their body and brain weight values but, there is a significant change in their alkaline phosphate reactive capillary profile values. Alkaline phosphate enzymes plays an important role in the functioning of the cerebral capillary activities.[3] The effect of darodipine on plasma concentration was also tested on a group of healthy male human volunteers. The result showed that darodipine resulted in the change in heart rate and diastolic blood pressure which is related to the plasma concentration.[4]
Darodipine (50–500 nM), the sensitivity of DMPO‐COO.− adduct decreased by more than that of the DMPO‐OH adduct and the concentration-dependent drop in signal intensity. It has additional preventive effects, because of its calcium antagonistics, against free-radical mediated electrophysiological alterations; it is likely because of the trapping of such radical molecules.
See also
[edit]- Isradipine, a structural isomer of darodipine
References
[edit]- ^ Gaggi R, Dall'Olio R, Roncada P, Gianni AM (June–July 1995). "Effects of isradipine and darodipine on serotonergic system of the rat brain". Pharmacology, Biochemistry, and Behavior. 51 (2–3): 183–7. doi:10.1016/0091-3057(94)00389-Z. PMID 7545305. S2CID 6704491.
- ^ Lamberti C, Bartolini A, Ghelardini C, Giotti A, Malmberg-Aiello P (Dec 1994). "Effects of the calcium-channel blockers darodipine and nimodipine on amnesia induced by three different hypoxic methods". Pharmacological Research. 30 (4): 359. doi:10.1016/1043-6618(94)80030-8.
- ^ Amenta F, Ferrante F, Mancini M, Sabbatini M, Vega JA, Zaccheo D (January 1995). "Effect of long-term treatment with the dihydropyridine-type calcium channel blocker darodipine (PY 108-068) on the cerebral capillary network in aged rats". Mechanisms of Ageing and Development. 78 (1): 27–37. doi:10.1016/0047-6374(94)01513-L. PMID 7603088. S2CID 42325236.
- ^ Sannita WG, Garbarino S, Gesino D, Massimilla S, Ogliastro C (September 1999). "Plasma concentration and CNS effects of Ca antagonists darodipine and nimodipine after single-dose oral administration to healthy volunteers". Neuropsychobiology. 40 (3): 158–70. doi:10.1159/000026614. PMID 10494052. S2CID 36345887.
Further reading
[edit]- Matucci R, Ottaviani MF, Barbieri M, Cerbai E, Mugelli A (December 1997). "Protective effect of darodipine, a calcium antagonist, on rat cardiomyocytes against oxygen radical-mediated injury". British Journal of Pharmacology. 122 (7): 1353–60. doi:10.1038/sj.bjp.0701525. PMC 1565083. PMID 9421282.